Your browser doesn't support javascript.
loading
Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.
Alves, Marco L; Dias, Fernando A L; Gaffin, Robert D; Simon, Jillian N; Montminy, Eric M; Biesiadecki, Brandon J; Hinken, Aaron C; Warren, Chad M; Utter, Megan S; Davis, Robert T; Sakthivel, Sadayappan; Robbins, Jeffrey; Wieczorek, David F; Solaro, R John; Wolska, Beata M.
Afiliación
  • Alves ML; Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois, Chicago, IL.
  • Dias FAL; Department of Physiology and Department of Cell Biology, Federal University of Parana, Curitiba, Brazil.
  • Gaffin RD; Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois, Chicago, IL.
  • Simon JN; Department of Physiology and Department of Cell Biology, Federal University of Parana, Curitiba, Brazil.
  • Montminy EM; Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois, Chicago, IL.
  • Biesiadecki BJ; Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois, Chicago, IL.
  • Hinken AC; Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois, Chicago, IL.
  • Warren CM; Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois, Chicago, IL.
  • Utter MS; Department of Physiology and Cell Biology, The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH.
  • Davis RT; Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois, Chicago, IL.
  • Sakthivel S; Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois, Chicago, IL.
  • Robbins J; Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois, Chicago, IL.
  • Wieczorek DF; Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois, Chicago, IL.
  • Solaro RJ; Division of Molecular Cardiovascular Biology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati.
  • Wolska BM; Division of Molecular Cardiovascular Biology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati.
Circ Cardiovasc Genet ; 7(2): 132-143, 2014 Apr.
Article en En | MEDLINE | ID: mdl-24585742
ABSTRACT

BACKGROUND:

Hypertrophic cardiomyopathy (HCM) is a common genetic disorder caused mainly by mutations in sarcomeric proteins and is characterized by maladaptive myocardial hypertrophy, diastolic heart failure, increased myofilament Ca(2+) sensitivity, and high susceptibility to sudden death. We tested the following

hypothesis:

correction of the increased myofilament sensitivity can delay or prevent the development of the HCM phenotype. METHODS AND

RESULTS:

We used an HCM mouse model with an E180G mutation in α-tropomyosin (Tm180) that demonstrates increased myofilament Ca(2+) sensitivity, severe hypertrophy, and diastolic dysfunction. To test our hypothesis, we reduced myofilament Ca(2+) sensitivity in Tm180 mice by generating a double transgenic mouse line. We crossed Tm180 mice with mice expressing a pseudophosphorylated cardiac troponin I (S23D and S24D; TnI-PP). TnI-PP mice demonstrated a reduced myofilament Ca(2+) sensitivity compared with wild-type mice. The development of pathological hypertrophy did not occur in mice expressing both Tm180 and TnI-PP. Left ventricle performance was improved in double transgenic compared with their Tm180 littermates, which express wild-type cardiac troponin I. Hearts of double transgenic mice demonstrated no changes in expression of phospholamban and sarcoplasmic reticulum Ca(2+) ATPase, increased levels of phospholamban and troponin T phosphorylation, and reduced phosphorylation of TnI compared with Tm180 mice. Moreover, expression of TnI-PP in Tm180 hearts inhibited modifications in the activity of extracellular signal-regulated kinase and zinc finger-containing transcription factor GATA in Tm180 hearts.

CONCLUSIONS:

Our data strongly indicate that reduction of myofilament sensitivity to Ca(2+) and associated correction of abnormal relaxation can delay or prevent development of HCM and should be considered as a therapeutic target for HCM.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Tropomiosina / Cardiomiopatía Hipertrófica / Calcio / Troponina I / Miofibrillas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Circ Cardiovasc Genet Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / GENETICA MEDICA Año: 2014 Tipo del documento: Article País de afiliación: Israel

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Tropomiosina / Cardiomiopatía Hipertrófica / Calcio / Troponina I / Miofibrillas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Circ Cardiovasc Genet Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / GENETICA MEDICA Año: 2014 Tipo del documento: Article País de afiliación: Israel